אנטרסטו 50 מג  이스라엘 - 히브리어 - Ministry of Health

אנטרסטו 50 מג

novartis israel ltd - sacubitril/valsartan as sodium salt complex - טבליות מצופות פילם - sacubitril/valsartan as sodium salt complex 24/26 mg - valsartan and sacubitril

אנטרסטו 50 מג  이스라엘 - 히브리어 - Ministry of Health

אנטרסטו 50 מג

novartis israel ltd - sacubitril/valsartan as sodium salt complex - טבליות מצופות פילם - sacubitril/valsartan as sodium salt complex 24/26 mg - valsartan and sacubitril

אנטרסטו 50 מג  이스라엘 - 히브리어 - Ministry of Health

אנטרסטו 50 מג

novartis israel ltd - sacubitril/valsartan as sodium salt complex - טבליות מצופות פילם - sacubitril/valsartan as sodium salt complex 24/26 mg - valsartan and sacubitril

סקטור 100 이스라엘 - 히브리어 - Ministry of Health

סקטור 100

unipharm ltd, israel - sacubitril/valsartan as sodium salt complex as sodium salt complex - sacubitril/valsartan as sodium salt complex as sodium salt complex 49/51 mg - valsartan and sacubitril

סקטור 200 이스라엘 - 히브리어 - Ministry of Health

סקטור 200

unipharm ltd, israel - sacubitril/valsartan as sodium salt complex as sodium salt complex - טבליות מצופות - sacubitril/valsartan as sodium salt complex as sodium salt complex 97/103 mg - valsartan and sacubitril

סקטור 50 이스라엘 - 히브리어 - Ministry of Health

סקטור 50

unipharm ltd, israel - sacubitril/valsartan as sodium salt complex as sodium salt complex - טבליות מצופות - sacubitril/valsartan as sodium salt complex as sodium salt complex 24/26 mg - valsartan and sacubitril

רמיפריל טבע  10 מג 이스라엘 - 히브리어 - Ministry of Health

רמיפריל טבע 10 מג

teva pharmaceutical industries ltd, israel - ramipril - טבליה - ramipril 10 mg - ramipril

טריטייס 1.25 מג 이스라엘 - 히브리어 - Ministry of Health

טריטייס 1.25 מג

sanofi israel ltd - ramipril - טבליה - ramipril 1.25 mg - ace inhibitors, plain - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.

טריטייס 2.5 מג 이스라엘 - 히브리어 - Ministry of Health

טריטייס 2.5 מג

sanofi israel ltd - ramipril - טבליה - ramipril 2.5 mg - ace inhibitors, plain - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.

טריטייס 5 מג 이스라엘 - 히브리어 - Ministry of Health

טריטייס 5 מג

sanofi israel ltd - ramipril - טבליה - ramipril 5 mg - ace inhibitors, plain - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.